Nasus Pharma announced positive Phase 2 topline results for NS002 intranasal epinephrine, demonstrating statistically significant improvements in early absorption versus EpiPen, with a pivotal study planned for Q4 2026. The company reported 2025 annual results including $4.3 million cash and $5.9 million net loss, with cash runway to Q2 2027 following $15 million private placement.
Key takeaways
NS002 Phase 2 results: statistically significant improvements in time to T100 and early therapeutic levels vs EpiPen
NS002 pivotal study initiation: Q4 2026, readout Q1 2027
NS003 and NS004 first-in-human studies: H2 2026
Cash, cash equivalents, marketable securities: $4.3 million as of Dec 31, 2025 (vs $0.3 million Dec 31, 2024)
Net loss: $5.9 million for year ended Dec 31, 2025 (vs $1.5 million 2024)
$15 million private placement closed Feb 2026, funding to Q2 2027